Journal of Bioanalysis & Biomedicine

Employing Engineered Extracellular Vesicles to Treat Specific Tumours

Abstract

Maria Sherry and Lewis Nixon*

Extracellular vesicles can be released by any cell, including prokaryotes and eukaryotes (EVs). EVs are vital for maintaining appropriate intercellular communication and internal environment balance because they include various cellular components such as RNA and surface proteins. EVs released from various tissues and cells have a wide range of features and functions (e.g., targeted specificity, regulatory ability, physical durability, and immunogenicity), making them a promising novel drug delivery and precision therapy alternative. The ability of EVs to transport anticancer medications for tumour therapy has been proven; additionally, the contents and surface material of EVs can be adjusted to improve their therapeutic efficacy in the clinic by increasing targeting potential and drug delivery effectiveness. By affecting the tumour microenvironment, EVs can control immune system function and hence slow tumour development.